Gasopres-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed to manage gastrointestinal disorders characterized by acid reflux, dyspepsia, and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility by enhancing esophageal and gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in the gastric parietal cells, providing effective relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of these two agents in Gasopres-DSR Capsule offers both symptomatic relief and promotes mucosal healing, making it suitable for patients with combined motility and acid secretion disorders. This medication should be administered orally as prescribed by a healthcare professional, with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with known hypersensitivity to either component, underlying cardiac conditions, or hepatic impairment. Regular monitoring is recommended to assess therapeutic efficacy and detect potential adverse effects such as extrapyramidal symptoms or electrolyte imbalances. Gasopres-DSR Capsule is contraindicated in patients with prolactinoma and should be used under strict medical supervision.